The observed enrichment of these minor variants suggests that they may encode for marginal reductions in susceptibility to sofosbuvir that cannot be measured with current in vitro systems.

It is possible that there is ongoing low-level replication selleck chemicals llc during treatment in some patients, perhaps owing to the presence of the HCC lesions, resulting in an enrichment of these mutants relative to wild-type and then transient detection at relapse/recurrence before wild-type dominates again. The clinical significance of the appearance of these minor variants remains to be determined. Because of the small size of this study, any conclusions must be considered preliminary in nature and require further evaluation in larger studies. Extrapolation of these results to all patients with HCV awaiting liver transplant is limited by the fact that the population studied comprised patients with compensated or mildly decompensated liver disease undergoing transplantation for hepatocellular carcinoma. At the time the study was designed,

the safety of sofosbuvir had not been evaluated in decompensated liver disease, and we therefore chose patients with a diagnosis of hepatocellular carcinoma meeting the Milan criteria so that the efficacy of the regimen for preventing post-transplant recurrence could be evaluated in patients with lower MELD scores, but who would be expected to undergo liver transplantation within 1 year. Studies of sofosbuvir regimens in patients with more advanced disease pretransplant are underway. The lack of a control arm to define PLX4032 efficacy and tolerability of the regimen was another shortcoming, although ascertainment bias

is unlikely given the universal recurrence of HCV in untreated patients. The majority of patients in this study had an undetectable viral load at the Arachidonate 15-lipoxygenase time of transplant and achieved pTVR. However, nonresponse and relapse were observed in a substantial proportion of patients, which led to re-infection of the allograft. It is unknown whether continuation of sofosbuvir and ribavirin through the post-transplant period in patients with a shorter duration of virologic suppression before transplantation could reduce rates of recurrence. Alternatively, higher rates of pTVR may be possible through the addition of another direct-acting antiviral to pretransplant sofosbuvir and ribavirin. In conclusion, therapy with sofosbuvir and ribavirin before liver transplantation prevented the recurrence of HCV infection after transplantation in 70% of patients who had undetectable levels of HCV RNA before transplantation. Given the burden of disease owing to HCV recurrence post-transplantation—the increased morbidity, mortality, and costs—these results provide hope for patients in need. The authors thank the patients and their families, the investigators, and site personnel.